More globally, these analyses validate PSIONIC as a predictive tool to predict TF activity in specific tumor settings, as shown for MITF in basal breast cancer, that expands its role in cancer beyond its known lineage-specific functions in melanoma. This evidence concerns the gene MITF and melanoma.